357 related articles for article (PubMed ID: 36243011)
41. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.
Sun X; Cui Z; Wang Q; Liu L; Ding X; Wang J; Cai X; Li B; Li X
Autoimmun Rev; 2024 Apr; 23(4):103530. PubMed ID: 38499168
[TBL] [Abstract][Full Text] [Related]
42. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Sano S; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 Feb; 50(2):e41-e68. PubMed ID: 36582113
[TBL] [Abstract][Full Text] [Related]
43. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
44. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
[TBL] [Abstract][Full Text] [Related]
45. Biologics for the primary care physician: Review and treatment of psoriasis.
Schadler ED; Ortel B; Mehlis SL
Dis Mon; 2019 Mar; 65(3):51-90. PubMed ID: 30037762
[TBL] [Abstract][Full Text] [Related]
46. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
47. Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis.
Yang EJ; Smith MP; Ly K; Bhutani T
Drug Des Devel Ther; 2019; 13():1993-2000. PubMed ID: 31354244
[TBL] [Abstract][Full Text] [Related]
48. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
Thibodaux RJ; Triche MW; Espinoza LR
Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
[TBL] [Abstract][Full Text] [Related]
49. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
50. Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab.
Dai C; Huang YH
Rev Esp Enferm Dig; 2024 Mar; 116(3):176-177. PubMed ID: 37314119
[TBL] [Abstract][Full Text] [Related]
51. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
Deepak P; Sandborn WJ
Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
[TBL] [Abstract][Full Text] [Related]
52. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.
Thomas SE; Barenbrug L; Hannink G; Seyger MMB; de Jong EMGJ; van den Reek JMPA
Drugs; 2024 May; 84(5):565-578. PubMed ID: 38630365
[TBL] [Abstract][Full Text] [Related]
53. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.
Macaluso FS; Orlando A; Cottone M
Expert Opin Biol Ther; 2019 Feb; 19(2):89-98. PubMed ID: 30571147
[TBL] [Abstract][Full Text] [Related]
54. IL-23 inhibitors for moderate-to-severe psoriasis.
Ibler E; Gordon KB
Semin Cutan Med Surg; 2018 Sep; 37(3):158-162. PubMed ID: 30215632
[TBL] [Abstract][Full Text] [Related]
55. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593
[TBL] [Abstract][Full Text] [Related]
56. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
57. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
Wu JJ; Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn A; Lowry S; Feldman SR; Armstrong A
J Dermatolog Treat; 2021 Nov; 32(7):693-700. PubMed ID: 32233828
[TBL] [Abstract][Full Text] [Related]
58. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P
Sci Rep; 2022 Sep; 12(1):15078. PubMed ID: 36064563
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?
de Brito M; Yiu ZZN
Am J Clin Dermatol; 2021 Sep; 22(5):587-601. PubMed ID: 34292509
[TBL] [Abstract][Full Text] [Related]
60. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
